Law360, New York (July 21, 2008, 12:00 AM ET) -- One business day after generic drug giant Teva Pharmaceutical Industries Ltd. announced its plan to buy out rival Barr Pharmaceuticals Inc. for nearly $8 billion, Roche Holdings AG on Monday revealed its own plans to purchase brand pharmaceutical company Genentech Inc. for almost $44 billion. The two deals could draw heavy antitrust scrutiny from regulators in both the U.S. and EU.
Antitrust regulators will be looking for signs of convergence between the merging couples and concerns that the mergers could harm the generic and brand drug...
Regulators To Take Close Look At Big Pharma Deals
To view the full article, take a free trial now.
